Luis Rodrigo

University of Oviedo

Dr. Luis Rodrigo, MD, is an Emeritus Professor of Medicine at the University of Oviedo, Spain. He has been the chief of Gastroenterology Service at the HUCA Hospital in Oviedo for more than forty years. He obtained a Ph.D. in 1975 and since then has developed a long career in teaching and research. He has published 707 scientific papers, 425 written in English and 282 in Spanish. He has participated as the main investigator in forty-five clinical trials and has directed forty doctoral theses. He has contributed actively to the formation of about 100 specialists in gastroenterology working in his hospital and other centers in Spain and abroad. He has written around thirty-five chapters in books and edited twenty-four books in gastroenterology and hepatology. His areas of interest are celiac disease and autoimmune-associated diseases.

16books edited

5chapters authored

Latest work with IntechOpen by Luis Rodrigo

This book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.

Go to the book